OBJECTIVE: This study investigated (1) the effect of octreotide-LAR (Sandostatin-LAR Depot; Novartis) on the enteroinsular axis in a biracial cohort of severely obese adults, (2) whether octreotide suppression of insulin secretion occurs by both a direct beta-cell effect and through mediating a glucagon-like peptide 1 (GLP-1) response, and (3) whether differences in GLP-1 concentrations could explain racial differences in insulin concentrations. DESIGN: Prospective, open-label trial using a pre-post test design. SETTING: Single university, clinical research center. SUBJECTS: In all, 42 healthy, severely obese Caucasian and African-American (AA) adults (93% female, 64% Caucasian, age=37.8+/-1.2 y, weight=123+/-4.2 kg, BMI=44.5+/-1 kg/m(2)), recruited through physician referral and newspaper ads, participated in the study. INTERVENTIONS: Indices of beta-cell activity, insulin and GLP-1 response before and during a 75-gm oral glucose tolerance test were determined before and after 24 weeks of octreotide-LAR. RESULTS: AA exhibited higher beta-cell activity, and insulin and GLP-1 concentrations than Caucasians. Octreotide-LAR suppressed the insulin and GLP-1 levels in both groups.
OBJECTIVE: This study investigated (1) the effect of octreotide-LAR (Sandostatin-LAR Depot; Novartis) on the enteroinsular axis in a biracial cohort of severely obese adults, (2) whether octreotide suppression of insulin secretion occurs by both a direct beta-cell effect and through mediating a glucagon-like peptide 1 (GLP-1) response, and (3) whether differences in GLP-1 concentrations could explain racial differences in insulin concentrations. DESIGN: Prospective, open-label trial using a pre-post test design. SETTING: Single university, clinical research center. SUBJECTS: In all, 42 healthy, severely obese Caucasian and African-American (AA) adults (93% female, 64% Caucasian, age=37.8+/-1.2 y, weight=123+/-4.2 kg, BMI=44.5+/-1 kg/m(2)), recruited through physician referral and newspaper ads, participated in the study. INTERVENTIONS: Indices of beta-cell activity, insulin and GLP-1 response before and during a 75-gm oral glucose tolerance test were determined before and after 24 weeks of octreotide-LAR. RESULTS: AA exhibited higher beta-cell activity, and insulin and GLP-1 concentrations than Caucasians. Octreotide-LAR suppressed the insulin and GLP-1 levels in both groups.
Authors: A Giustina; A Girelli; M G Buffoli; A Cimino; F Legati; U Valentini; G Giustina Journal: Diabetes Res Clin Pract Date: 1991-10 Impact factor: 5.602
Authors: Hiroshi Yamamoto; Charlotte E Lee; Jacob N Marcus; Todd D Williams; J Michael Overton; Marisol E Lopez; Anthony N Hollenberg; Laurie Baggio; Clifford B Saper; Daniel J Drucker; Joel K Elmquist Journal: J Clin Invest Date: 2002-07 Impact factor: 14.808
Authors: R H Lustig; F Greenway; P Velasquez-Mieyer; D Heimburger; D Schumacher; D Smith; W Smith; N Soler; G Warsi; W Berg; J Maloney; J Benedetto; W Zhu; J Hohneker Journal: Int J Obes (Lond) Date: 2006-02 Impact factor: 5.095
Authors: Stephanie T Chung; Mirella Galvan-De La Cruz; Paola C Aldana; Lilian S Mabundo; Christopher W DuBose; Anthony U Onuzuruike; Mary Walter; Ahmed M Gharib; Amber B Courville; Arthur S Sherman; Anne E Sumner Journal: J Clin Endocrinol Metab Date: 2019-01-01 Impact factor: 5.958
Authors: Robert H Lustig; Michele L Mietus-Snyder; Peter Bacchetti; Ann A Lazar; Pedro A Velasquez-Mieyer; Michael L Christensen Journal: J Pediatr Date: 2006-01 Impact factor: 4.406
Authors: Sara F Michaliszyn; SoJung Lee; Fida Bacha; Hala Tfayli; Lama Farchoukh; Andrea Mari; Ele Ferrannini; Silva Arslanian Journal: Pediatr Diabetes Date: 2016-01-22 Impact factor: 4.866